Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $14.20 Average Target Price from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.20.

AMRX has been the subject of several recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Barclays started coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, March 6th. Finally, Truist Financial raised their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. lifted its stake in Amneal Pharmaceuticals by 75.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after buying an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $13,833,000. Morgan Stanley increased its holdings in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Amneal Pharmaceuticals by 1,440.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock valued at $11,790,000 after purchasing an additional 1,062,045 shares in the last quarter. Finally, Penn Capital Management Company LLC acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $12,655,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $12.35 on Friday. The company has a market cap of $3.89 billion, a P/E ratio of 53.70 and a beta of 1.32. The business’s 50 day moving average price is $13.45 and its 200-day moving average price is $12.30. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $15.42.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.